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EpendymaThe delicate microenvironment of the central nervous system (CNS) is protected by the blood–brain barrier
(BBB) and the blood–cerebrospinal ﬂuid barrier (BCB). These barriers function in distinct CNS compartments
and their anatomical basis lay on the junctional proteins present in endothelial cells for the BBB and in the
choroidal epithelium for the BCB. During neuroinﬂammatory conditions like multiple sclerosis (MS) and its
murine model experimental autoimmune encephalomyelitis (EAE), activation or damage of the various
cellular components of these barriers facilitate leukocyte inﬁltration leading to oligodendrocyte death,
axonal damage, demyelination and lesion development. This manuscript will review in detail the features of
these barriers under physiological and pathological conditions, particularly when focal immune activation
promotes the loss of the BBB and BCB phenotype, the upregulation of cell adhesion molecules (CAMs) and
the recruitment of immune cells.Laboratory (Y-3608), Center of
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The blood–brain barrier (BBB) and the blood–cerebrospinal ﬂuid
barrier (BCB) are a complex vasculature network that forms a
continuous cellular barrier between the central nervous system
(CNS) and the systemic circulation [2]. Most of the important
metabolic exchanges that are critical to CNS homeostasis occur
through this tightly regulated network. The BBB and to some extend
the BCB are thus generally considered to be the structures responsiblefor providingnutrients, oxygen, ions, vitamins and co-factors aswell as
peptides and proteins to the CNS [33]. By extension, they have been
described as the limiting factor to prevent the entry of xenobiotics,
toxic metabolites and immune cells into the CNS. The functionality of
the BBB is achieved through intricate interactions between BBB
endothelial cells (BBB-ECs), perivascular astrocytes, pericytes and
neighbouring CNS cells, creating a dynamic and multi-cellular
component named the neurovascular unit (NVU) [82]. As for the BCB
the anatomical basis of the barrier is on the epithelial cells making up
the choroid plexus (CP) [56], with the soluble factors and/or contact-
mediated mechanisms responsible of the barrier function to be
established. The maintenance of a precisely regulated biochemical
and immunological microenvironment is essential for proper CNS
function and changes in its delicate balance have been associated with
CNS pathologies, such as multiple sclerosis (MS) [66].
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the CNS. While its aetiology remains unknown, currently available
data suggest that a combination of factors (environment, viruses and
dietary conditions), in conjunction with genetic susceptibility might
drive the inﬂammatory response against antigenic determinants that
are speciﬁcally expressed in the CNS [66,130,156]. Critical aspects of
MS lesion formation include (i) inﬂux of activated and CNS-speciﬁc
immune cells from the peripheral vascular compartment to the CNS
tissue and (ii) nervous tissue damage, as best exempliﬁed by the
presence of demyelinating lesions (called plaques) located in the
white and to some extend in the cortical grey matter. Despite recent
debate on the presence of a relative importance of white vs. grey
matter lesions, a typical and universal feature of MS remains that
lesions are scattered throughout the CNS parenchyma and are
characterized by extensive immune cell inﬁltration (lymphocytes,
monocytes, dendritic cells, etc.) in the perivascular space of small and
medium caliber vessels [112,113]. These inﬁltrating cells may further
trafﬁc into the CNS parenchyma, causing demyelination, oligoden-
drocyte death and axonal damage [55,130]. Activated leukocytes
locally release inﬂammatory cytokines and chemokines leading to
focal immune activation of ECs, loss of the BBB and BCB phenotype,
upregulation of cell adhesion molecules (CAMs) and the recruitment
of additional immune cells, often called bystander leukocytes [21].
The inﬁltrated cells subsequently secrete additional cytokines and
chemokines that may either enhance or dampen the inﬂammatory
process. Although peripheral blood leukocyte inﬁltration plays an
essential role in MS lesion development, there is also evidence
suggesting that BBB dysfunction precedes immune cell inﬁltration.
This may only reﬂect CNS innate immune cell (microglia) activation
and/or astrocyte dysfunction and does not necessarily means that
primary BBB dysfunction is the leading cause of MS lesion formation.
Nevertheless and while a primary BBB or BCB dysfunction is not
considered to be the cause of MS, recent evidence suggest that
immune-mediated activation (or damage) of the various BBB cellular
components signiﬁcantly contributes to MS lesion development and
expansion [132]. In this manuscript we will review some of the key
observations that associate loss of BBB phenotype with CNS
inﬂammatory events and MS lesion formation. The mechanisms of
inﬂammation-induced BBB disruption, CAM upregulation and im-
mune cell trafﬁcking to the CNS will be discussed in detail. These
observations will be expanded to review the changes in the BCB
during MS and its role in immune cell inﬁltration to the CNS.
2. BBB under physiological conditions
CNS vessels associated with the BBB are formed by highly
specialized ECs that inhibit the transcellular and paracellular diffusion
of macromolecules and cells due to their distinctive structural and
functional features [71,104]. These unique characteristics are in part
due to interactions with pericytes, astrocytes and neurons in what is
now known as the NVU. In contrast to vessels of peripheral organs, the
CNS-ECs have specialized transport systems, low pinocytic activity,
higher mitochondrial volume fraction and lack transendothelial
fenestrations [19]. Due to the very sparse pinocytic activity, the
paracellular ﬂux is limited. Moreover, the uptake of essential
molecules is mediated through speciﬁc carrier and transport systems
[71,104]. In addition, the paracellular cleft between adjacent lateral
endothelial membranes is almost completely sealed because of the
presence of continuous strands of junctional complex proteins that
include tight junctions (TJs) [79,104,200,207] and adherens junctions
(AJs) [174].
3. Cellular composition of the BBB
Glial cells of the NVU are key contributors to the BBB phenotype.
Unique communication between BBB-ECs and perivascular cells allowsfor complex signaling events between CNS glial cells and the CNS
endothelium. These intricate cellular interactions control and maintain
BBB function (TJ maintenance, metabolic and specialized transporter
expression). Such signaling events allow for a rapid regulation and
remodeling of the BBB, a phenomena crucial to maintain CNS
homeostasis in response to physiological and pathological stimuli
[2,82,156,158]. Three features of the NVU are essential for proper BBB
functioning: the pericytes, the astrocytes and the basement membrane
(BM).
Pericytes provide physical support to ECs and also play a role in the
maturation and maintenance of the BBB by secreting growth factors
and extracellular matrix components. The number of pericytes
associated with blood vessels varies among different types of vessels,
with those in the CNS exhibiting the highest pericyte coverage [13]. In
addition, in vitromodels of the BBB normally used co-cultures of BBB-
ECs and astrocytes, but when pericytes are added to the system, the
triculture system reorganize into stable capillary-like structures,
demonstrating the important role of pericytes in the formation and
maintenance of the vasculature and the BBB [84,109]. Pericytes are
known to participate in these process by secreting transforming
growth factor (TGF)-β [50], angiopoietins [87], platelet-derived
growth factor (PDGF)-B [119] and sphingosine-1-phosphate (S1P)
[13]. Pericytes, through N-cadherin-dependent binding to ECs [69],
promote vascular maturation/integrity [136] and participate in
reducing BBB permeability. Pericytes also induce angiogenesis and
are known to support cerebral blood ﬂow in experimental models of
ischemia and brain tumors [83,108]. Although pericytes have
multifunctional roles in BBB development and maintenance, their
exact functions remain under intense investigation [17,136]. Finally, it
has been suggested that pericytes participate in immune reactions as
they performed antigen presenting cell-like activities. In this regard,
CNS pericytes are known to express major histocompatibility
complex-II (MHC-II), possess phagocytic activities and absorb soluble
molecules delivered into the blood or CSF [17,18]. However, this
particular function still in debate, as studies clearly demonstrating that
this phenotype is exclusively due to pericytes and no perivascular
macrophages are lacking.
Astrocytes are crucial constituents of the NVU and are important
inducers of BBB properties. Astrocytic endfeet ensheathe 99% of the
surface of the brain microvessels and are separated only by a thin but
compact BM [82]. Perivascular astrocytic processes are a speciﬁc
feature of CNS microvessels and their formation coincides with the
development of barrier properties [152]. Astrocyte–EC interactions
regulate ECs proliferation, angiogenesis, transporter protein expres-
sion, TJs protein expression, TJ morphology and are known to
modulate inﬂammatory responses in the CNS [1,2,138,156,158,219].
Primary BBB-ECs isolated and cultured in vitro rapidly lose some of
their BBB-features, such as P-glycoprotein and TfR expres-
sion [35,114]. Interestingly, BBB function can be reinstated by co-
culturing BBB-ECs in the presence of astrocytes or astrocyte
conditioned media (ACM) [158,191,212]. These observations under-
score the importance of signals supplied by astrocytes and provide
evidence that factors needed for reliable BBB function are at least
partly soluble and secreted [138]. However, the exact identity of the
soluble and contact-dependent factors provided by astrocytes still
remains largely unknown. Potential candidates include members of
the ﬁbroblast growth factor (FGF) family [165], glia-derived neuro-
tropic factor (GDNF) [91], TGF-β [50], Src-suppressed C kinase
substrate (SSeCKS) [116], Meteorin [150], angiotensinogen [212]
and more recently members of the Hedgehog family [7]. The current
view is that astrocytes regulate various aspects of BBB physiology
using a multitude of factors with redundant functions and that
understanding the complex astrocyte–BBB-EC interactions under
physiological and pathological conditions might lead to the develop-
ment of novel therapeutic strategies to either enhance or conversely
restrict BBB permeability.
Fig. 1. BBB changes inMS. Occludin andVE-cadherin stainings are shown in green,GFAP in
red (upper panels), laminin in red (lower panels) and the TOPRO-3-stained nuclei in blue.
Scale bars indicate 50 μm, vessels are marked by asterisks and i denotes immune
inﬁltrates. Zipper like structures of intact junctions are seen in normal-appearing white
matter (NAWM) vessels (left panels). Decreased expression and focal degradation
(arrowheads) of TJ (occludin) and AJ (VE-cadherin) proteins is detected in vessels
associated with lesions (right panels). Astrogliosis is found as increase numbers of GFAP+
endfeet (arrows) in the periphery of lesional vessels (upper right panel). Laminin
expression in NAWM vessels is seen as a smooth and continuous layer labeling the basal
lamina (lower left panel). In active lesions, laminin expressiondecreases in the endothelial
and parenchymal basement membranes (arrowheads) (lower right panel).
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composed of several extracellular matrix (ECM) components, includ-
ing laminins [96] (Fig. 1 lower left panel), ﬁbronectin [195],
dystroglycans [47], collagen type IV and heparin sulfate proteoglycans
[194,195]. Ultrastructural and immunoﬂuorescent studies have
shown that this structure is made of two membranes closely
associated with the brain microvasculature: these are referred to as
the endothelial and the parenchymal BM [82]. The BM functions as a
tissue (anatomical) scaffold onwhich NVU cells are attached and form
a substrate for cellular differentiation and gene expression. Endothe-
lial-, astrocyte- and to a lesser degree pericyte-derived extracellular
matrix proteins enhanced BBB integrity, demonstrating the impor-
tance of glial matrix constituents [81]. Soluble factors secreted by glial
cells can be captured by ECM proteins depending on their charge, and
thus the ECM is regarded as a structure which increases local
concentration and paracrine potency of biologically active molecules.
BBB-ECs constitutively express a number of integrins important in EC
adhesion to the basal lamina and alterations in the expression of BBB
basal lamina or integrins correlates with BBB property breakdown
[47,49].
4. Adherent and tight junctions: molecular fences and dynamic
signaling regulators of BBB integrity
The intercellular spaces of tight and impermeable biological
barriers are sealed by large molecular complexes called TJs. In the
BBB and in other biological barriers, TJs are composed of large multi-
protein complexes that mediate tight intercellular contacts between
adjacent cells and act as molecular fences [149,219]. TJs consist of at
least three known types of transmembrane proteins including
occludin, claudins and junctional adhesion molecules (JAMs) [200].
The extracellular loops of these proteins form a paracellular barrier
that selectively excludes most blood-borne substances from the CNS.
While occludin is not required for the structural integrity of the TJs, as
mice deﬁcient in occludin can still form proper functioning TJs [167],
claudins are essential components of BBB maintenance [127,140].
Claudins and occludin create an impermeable seal between cells
through homophilic and heterophilic binding of their extracellular
loops [196]. Claudin-3 and -5 are preferentially expressed in brain ECs
and play an important role in vessel permeability and angiogenesis
[140]. JAM-A localizes to the intercellular TJs of murine [9,15,200] and
human CNS-ECs [200] where it promotes cell to cell contact in a
homophilic manner. Although its role in restricting BBB permeability
remains unclear, JAM-A is known to be implicated in leukocyte
transmigration [124], angiogenesis [135] and as a receptor for viruses
[22]. Although JAM-B and -C have been detected in murine [15] and
porcine [134] CNS-ECs, their expression and role at the human BBB
remain to be fully elucidated.
The cytoplasmic region underlying the TJ transmembrane proteins
contains a vast number of adaptor proteins that mediate the link
between the TJ proteins and the actin microﬁlaments. Claudins,
occludin and JAM-A interact with a variety of structural proteins and
therefore regulate a wide array of signaling pathways essential for EC
survival and TJ assembly, maintenance and regulation [19]. Zona
occludens (ZO-1, -2 and -3) and the membrane-associated guanylate
kinase inverted proteins (MAGI-1 and -3) are important adaptor
proteins of the membrane-associated guanylate kinase (MAGUK)
protein family [78]. They are known to bridge and immobilize
membrane-anchored TJ proteins with actin ﬁlaments in EC and
epithelial barriers. These adaptor proteins contain numerous pro-
tein-protein interaction domains, such as SH3 and PDZ [78]. These
domains interact with the cytoplasmic tail of integral membrane
protein and bind to other adaptor proteins, leading to the formation of
intricate signaling scaffolds. Several other intracellular proteins have
been shown to be involved in the biogenesis and the maintenance of
TJs and they include: AF-6, cingulin, Ca2+-dependent serine proteinkinase (CASK) and 7H6 antigen as well as various signaling molecules
like RhoA and Rac [77,125,206,218].
AJs also contribute to the low permeability of the BBB and BCB by
mediating the cell to cell adhesion in endothelium and epithelium
[46]. They partially regulate paracellular permeability and consist of
the transmembrane proteins cadherins and the cytoplasmic proteins
catenins. The adhesive properties of AJs are due to the homophilic
interactions between the extracellular domains of calcium-dependent
cadherins on the surface of adjacent cells, while catenins are the
linkers with the actin cytoskeleton and support the formation of
255J.I. Alvarez et al. / Biochimica et Biophysica Acta 1812 (2011) 252–264adhesive contacts between cells [19,111]. ECs express high levels of
vascular endothelial (VE)-cadherin, also known as cadherin-5 and the
neuronal cadherin (N-cadherin) [25]. VE-cadherin, as most of the
members of this family, is linked to the catenins p120, β-catenin and
plakoglobin through its cytoplasmic tail [45]. This AJ complex binds to
α-catenin and interacts with the actin-binding proteins α-actinin,
ajuba, zonula occludens-1 (ZO-1) among others to link the cytoskel-
eton with the cellular membrane [111,159,204]. Clustering of VE-
cadherin at cell–cell contacts promotes the formation of multimolec-
ular complexes that comprise signaling, regulatory and scaffold
proteins [46]. In addition, VE-cadherin is involved in vascular
permeability via the induced phosphorylation and internalization
induced by vascular endothelial growth factor (VEGF) and by its
association with vascular endothelial tyrosine phosphatase [68,141].
The levels of N-cadherin expression in ECs are comparable to VE-
cadherin, but it has a diffuse distribution on the cellular membrane
with poor clustering in the junctional complexes [46]. Thus, it has
been suggested that N-cadherin does not play a role at the level of the
junctional complex and rather acts at heterotypic cell–cell contacts
between ECs and pericytes [69,148]. Other atypical members of the
cadherin family, such as T-cadherin (cadherin-13) and P-cadherin, are
variably expressed in different types of ECs [92]. T-cadherin lacks the
transmembrane and intracellular domains and it is not enriched in AJs
[92]. T-cadherin primarily functions as a signaling molecule that
regulates barrier function through a complex signaling network [10]
and also suppresses angiogenesis by inhibiting migration of ECs [166].
Regarding catenins, their exact mechanism of action to promote
cadherin-cytoskeleton contact is not fully understood, but it is
proposed that cadherin clustering promotes the recruitment of
monomeric α-catenin when cells establish cell–cell contacts
[137,155]. As α-catenin is bound to cadherin through β-catenin or
plakoglobin, molecules ofα-cateninwould detach from cadherins and
associate to form homodimers that promote actin bundling. Thus, the
association of VE-cadherin with catenins is certainly required for full
cellular control of endothelial permeability and junctional complex
stabilization [46]. In addition, there is interplay between TJs and AJs as
assembly of TJs is inﬂuenced by the interaction between ZO1 and
catenins [127].
5. The blood–cerebrospinal ﬂuid barrier
An intact BBB and BCB are essential for maintenance of a healthy
CNS. Upon inﬂammatory conditions leukocyte inﬁltration into the
CNS also occurs in the ventricles via the CPs [62,173]. These structures
are extensions of the ependymal lining into the ventricles and are
made up of highly specialized cuboidal and ciliated epithelial cells
surrounding a stroma with blood vessels lacking BBB properties. The
main function of CPs is to secrete cerebrospinal ﬂuid (CSF) which is
important for mechanical protection of the brain, regulation of the
intracranial volume, distribution of neuroendocrine factors and
buffering of extracellular ﬂuid ions and other solutes [30,175,208].
The BCB is the cellular boundary between choroid epithelial cells that
separates the blood from the CSF and its anatomical basis is due to the
junctional proteins located between these cells. TJs of the BCB are
found directly underneath the microvilli of choroid cells forming
parallel strands that are sparsely interconnected according to freeze-
fracture studies [62]. Studies in humans and rodents have shown that
choroid cells express the TJ proteins ZO1, occludin, claudin-2, -3, -11
and JAM-A [8,120,207]. The presence of AJ proteins has been
examined and cadherin, α-catenin and β-catenin are also found in
choroid epithelial cells [8].
6. BBB changes during MS lesion formation
Changes at the level of the BBB during inﬂammation are related to
two main processes: (i) BBB disruption, which implies leakage andalteration of junctional components, and (ii) BBB activation, which
relates to the capacity of ECs, astrocytes and possibly pericytes to
express and secrete immune factors able to inﬂuence the recruitment,
the effector functions and the survival of leukocytes entering the
brain.
Under physiological conditions, the assembly and maintenance
of TJs are tightly regulated events. Although the function of TJs and
AJs as molecular fences between adjacent cells is well understood,
the role of TJs in immune cell migration between adjacent ECs and
epithelial cells at the BBB and the BCB remains to be deﬁned. Under
neuroinﬂammatory conditions, as is the case in MS, TJ and AJ
deregulation is associated with loss of BBB permeability and
increase solute and immune cell inﬁltration in the CNS [151].
Alterations in the BBB can be identiﬁed through histological analysis
in post-mortem samples or clinically by using imaging techniques
such as MRI (magnetic resonance imaging). Such changes in the BBB
are thought to occur at the early phase of lesion formation, as
immune cell inﬁltration originates in the surroundings of paren-
chymal microvessels [66,219]. During the early stages of MS, the
inﬂammatory state and the leakiness of the blood vessels are
thought to facilitate the movement of leukocytes and immune
soluble mediators exacerbating the inﬂammatory process and
leading to multifocal perivascular inﬁltrates. Such inﬁltrates are
rich in antigen presenting cells and lymphocytes, predominantly
cytotoxic T cells and T helper (Th)1 and Th17 T cells, which are
known to play an important role in demyelinating perivascular
areas [5,64,89,97,98,131]. In addition, alterations in the BBB and
inﬁltration of immunopathogenic leukocytes are accompanied by
edema, axonal loss and gliosis [55,65,66]. All these features
potentially lead to reversible neuronal dysfunction early in the
disease process, whereas permanent neurological deﬁcits are
currently seen as the result of a long-term immune-dependant
neurodegenerative process [26,192].
In MS, the breakdown of the BBB is thought to be transient,
although recurrence may be observed at the same or different
locations within interval of weeks, months or even years [80]. The
subsequent progress and lesion development is irregular and involves
additional phases of BBB leakage, immunologically mediated demy-
elination and various degrees of axonal transection [55,203]. It is well
recognized that the expression and organization of junctional proteins
are known to change during neuroinﬂammatory and infectious
processes [9,79]. To assess the state of the BBB and particularly its
anatomical components has been a difﬁcult task in MS patients due to
the scarcity of frozen post-mortem samples and the technical
difﬁculties in determining expression of various junctional complex
proteins in CNS tissue. Thus, these constraints have limited the analysis
of BBB pathophysiology in the different type of lesions. Analysis of CNS
vessels in MS has shown alterations in the expression of TJ and AJ
proteins within lesions when compared with the vasculature in the
normal-appearing white matter (NAWM) [101,147,154]. Some recent
images from our lab depicting TJ and AJ alterations in MS lesions are
found in Fig. 1. Abnormalities in the expression of junctional proteins
coincide with perivascular astrogliosis (Fig. 1 upper right panel),
serum protein leakage and it has been proposed that dysfunctional TJs
and subsequently impaired endothelial function allow more cells and
immunologically active molecules to access the CNS, enhancing
demyelination, axonopathy and tissue injury [147]. In addition, the
expression pattern of junctional proteins in active and inactive white
matter lesions, and in NAWM within acute MS, PPMS (primary
progressive MS) and SPMS (secondary progressive MS) indicates a
higher degree of endothelial abnormalities in active (40%) vs. inactive
lesions (23% in PPMS and 37% in SPMS). Surprisingly, 13% of the
vasculature in NAWM displayed abnormalities associated with BBB
permeability, although to a lesser extent when compare to lesions
[117]. Thus, abnormalities in the NAWM and presumably in the
normal-appearing grey matter (NAGM) may represent the subtle
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lesions, and such disturbances could correspond to the largely
uncharacterized ﬁrst steps of lesion formation, called either nascent
or pre-active lesions [85,197].
7. Role of immune soluble mediators in TJ alterations
MS and EAE are immune CNS mediated disorders characterized
by immune cell inﬁltration and upregulation of pro-inﬂammatory
cytokines and chemokines such as IL-1β, IL-17, IL-22, IFN-γ and
CCL2 among others [16,97,98,122]. Most of these immune media-
tors are released by leukocytes during transmigration, and within
the CNS and aside of promoting and expanding immune cell
activation they can also affect the integrity of the BBB. Elevated
levels of TNF-α and IL-1β in EAE are associated with changes in the
BBB permeability [70] and such increase has been also demon-
strated in the CSF of MS patients [177,178]. In vivo and in vitro
studies have shown that IL-1β indirectly destabilizes the BBB by
inducing expression of matrix metalloproteinase-9 (MMP-9)
[28,184,201], an enzyme known to cleave occludin, ZO-1, claudin-
5 and other junctional complex associated molecules [14,24,215].
Degradation/downregulation of TJ proteins correlate with the
elevated levels of MMP-9 expression reported in MS patients. IL-
17 and IL-22 have also been associated with changes in the BBB. In
this regard, treatment of primary cultures of human BBB-ECs with
both cytokines induced alterations in the BBB permeability that
coincided with decrease expression of occludin and ZO-1. These
ﬁndings correlated with the reduction of both proteins in CNS blood
vessels highly inﬁltrated in EAE and MS sections [98] a ﬁnding that
was recently conﬁrmed by Huppert [88]. In ECs, TNF-α is able to
induce intercellular gaps that resulted from loss of VE-cadherin in
AJs [205]. TNF-α can also affect barrier permeability by upregulat-
ing the expression of NF-κB, which induces the transcription of
myosin light chain kinase (MLCK), a factor known to induce
internalization of TJ proteins [143]. Co-stimulation with IFN-γ and
TNF-α are known to affect EC permeability by affecting the cellular
distribution of JAM-A, claudin-5 and by inducing focal loss of
VE-cadherin [146,211]. In addition, IFN-γ induces actin restructura-
tion and decreases the protein levels and the subcellular localiza-
tion of ZO-1 [27,217]. In epithelial cells IFN-γ stimulation promotes
endocytosis of occludin, claudin-1 and JAM-A but not ZO-1 or AJ
proteins [31]. Conversely, removal of IFN-γ results in repositioning
of occludin, JAM-A and claudin-1 in the cell membrane, from intra-
cellular pools [32].
Cytokines, oxidative stress and various growth factors can also
affect the stability of the BBB, by modifying the phosphorylation state
of the TJs. For instance, VEGF affects the barrier permeability by
increasing the phosphorylation of occludin and ZO-1 [11], an effect
reversed by treatment with dexamethasone [12]. The chemokine
CCL2 (formerly known as MCP-1) is also known to affect the
permeability of the BBB and as VEGF, it induces phosphorylation of
occludin, ZO-1, ZO-2 and claudin-5, at least in murine systems [185].
CCL2 also induces loss of occludin, claudin-5, ZO-1, ZO-2 through
endocytosis mediated events [186,187]. Monocytes/macrophages also
participate in the CCL2 induced changes in BBB permeability as
interactions between monocytes and BBB-ECs also result in phos-
phorylation of TJ proteins [151,187]. Reactive oxygen species, in
particular H2O2, has been shown to promote BBB disruption
[63,88,115,169] and to favor immune cell attachment to BBB-EC
[172]. This oxidant-mediated disruption and activation of the BBBwas
found to be detrimental in animal models of MS, as elegantly proven
by Schreibelt [169,170] and extensively reviewed in 2007 [171].
In contrast to the detrimental effect of pro-inﬂammatory cyto-
kines, other immune soluble mediators such as IFN-β and IL-25
promote BBB integrity and impermeability. IFN-β is a type I IFN with
immunodulatory effects that has been used for the treatment of MSfor over 15 years [86,216]. In vitro and in vivo studies have shown that
IFN-β increases the transendothelial resistance, reduces permeability,
stabilizes the barrier function [106,107] and induces cell surface
shedding of adhesion molecules on CNS-ECs [34,73]. On the other
hand, IL-25 is a member of the IL-17 family and is expressed in CNS-
ECs. Stimulation of ECs with inﬂammatory cytokines such as TNF-α,
IL-17, IFN-γ and IL-1β reduces IL-25 expression, a pattern also
observed in active MS lesions and in EAE [183]. IL-25 seems protective
for the BBB, as the reduced expression of claudin-5, JAM-A and
occludin induced by TNF-α can be re-established upon treatment
with IL-25 [183]. Taken together, these studies provide strong
evidence that numerous cytokines play important role in regulating
multiple aspects of TJ proteins and ultimately BBB permeability. In the
following sections, we will explore additional roles of cytokines at the
BBB/NVU, especially regarding expression of adhesion molecules and
the migration of immune cells.
8. Alterations in the basal lamina during MS and EAE
In addition to the junctional complexes between ECs, the basal
lamina surrounding the brain vasculature adds another layer of
complexity to the BBB. Therefore, alterations in the structure and
organization of this layer may affect the permeability of the barrier and
subsequently the movement of leukocytes and immune mediators into
the brain. Following migration through the CNS endothelium, leuko-
cytes accumulate within the perivascular space and cross the paren-
chymal BM to enter the brain [180]. To accomplish this, immune cells
produce MMPs and other enzymes involved in the degradation and
remodeling of the BM [5]. In the murine model of MS, experimental
autoimmune encephalomyelitis (EAE), as well as in human MS it has
been shown that T cell andmacrophage derivedMMP-2 and -9 support
leukocyte entry into the CNS parenchyma by speciﬁcally cleaving the
endothelial BM and dystroglycan, a receptor that anchors astrocyte
endfeet to the parenchymal BM via high afﬁnity interactions with ECM
[4,20,74]. As a result of the neuroinﬂammatory environment in CNS
vessels and the expression ofMMPs,MS lesions are characterized by the
presence of irregular and discontinuous BMs and deposition of ECM
components within the perivascular inﬁltrates [195] (Fig. 1 lower right
panel and Fig. 2B and D). Regarding their function during the course of
MS, it is has been shown in EAE that expression of laminins 411 and 511,
which are found in the endothelial BM, is inﬂuenced by proinﬂamma-
tory cytokines and their pattern of expression is associatedwith areas of
T cell inﬁltration [180]. Thus, inﬁltrates are found in vessels expressing
laminin 411 and low levels of 511, while in the absence of 411, laminin
511 is ubiquitously expressed in theCNSvasculature and this phenotype
is associated with low T cell inﬁltration and milder disease [213]. These
data indicate that the BM is not only a physical component of the BBB, as
it can actively support the transmigration of T cells into the CNS through
the interaction laminin α4-integrin α6β1 [213] and by acting as a
reservoir of chemotactic agents, such as chemokines [123].
9. BCB disruption in MS and EAE
In contrast to parenchymal microvessels, which possessed BBB
properties, the basis of the barrier properties in the CP lays on the TJs of
the choroidal cells. The choroidal vessels are fenestrated and lackbarrier
properties, thus migration of immune cells within the CPs should be
easily achieved when compare with their counterparts in parenchyma
[208]. But, the few evidence available regarding leukocyte migration in
the CPs indicates that a small number of cells move through this barrier
and in fact, the number of leukocytes accumulating in the choroidal
stroma is very low when compare to the perivascular inﬁltrates of
parenchymal lesions. Studies in EAE have shown aberrant cellular
morphology characterized by electron-dense and electron-light choroid
cells. In these animals the junctions seemed to be structurally intact,
although the distribution and the ratio of different junctional proteins
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there are no studies addressing the mechanisms involved in the
moderate changes seen in the anatomical components (junctional
proteins) of the BCB during EAE. Damage of the BCB inMS has been also
poorly explored and most studies on this topic are focused to
understand the migration of leukocytes through the CP and the
mechanisms associated with this process [164].
10. Leukocyte transmigration through the CNS barriers
Under physiological conditions, a low number of immune cells
continuously access the CNS in a process called immune surveillanceFig. 2. Differential expression of cell adhesion molecules (CAMs) in inﬂamed ECs. The expres
(A and C) and in MS tissues (B and D). The CAMs are depicted in green, the ECM component l
(C) expression is upregulated on the surface of BBB-ECs when stimulated with the cytokine
vessels (arrow) and they are upregulated in vessels associated with pre-active lesions display
panels). ICAM-1 and VCAM-1 expression is high in vessels (asterisk) associated with active
expression decreases in the endothelial and parenchymal basement membranes with lamin[60]. Immune cells can enter the CNS through 3 distinct routes; the ﬁrst
two involve the BBB via pial vessels to the subarachnoid space or via brain
microvessels to the parenchyma. In the third route immune cells can gain
access to the CNS in ventricular areas through the non-BBB vessels of the
choroidal stroma and then through the choroid cells forming the BCB
[56,60,162]. A fourth route has been suggested and involves migration
from subependymal vessels in innervating leptomeninges and through
the ependyma into the ventricles [8]. During physiological immunosur-
veillance, leukocytesmigrate into theCNSvia themeninges and theBCBat
the CPs; while all the known routes of migration are effective during
inﬂammatory conditions [8,102,162]. Transendothelial leukocyte migra-
tion through theBBB is amulti-stepprocess characterizedby (i) leukocytesion of the CAMs ICAM-1 and VCAM-1 is shown in cultures of human primary BBB-ECs
aminin in red and the nuclei in blue. Scale bars indicate 10 μm. ICAM-1 (A) and VCAM-1
s IFN-γ and TNF-α during 16 h. ICAM-1 (B) and VCAM-1 (D) are expressed in NAWM
ing inﬁltration of leukocytes (arrowheads) and partial loss of laminin expression (upper
MS lesions and it is even detected in some inﬁltrating cells (i) (lower panels). Laminin
in+ fragments (large arrowheads) found in perivascular areas (lower panels).
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of leukocytes and integrin avidity changes by chemokine stimulation ofG-
protein-linkedreceptors, (iii) arrest andadhesionstrengtheningmediated
by endothelial CAMs and leukocyte integrins and (iv) diapedesis [118].
11. Involvement of selectins, CAMs and integrins in leukocyte
tethering and rolling in the BBB during EAE and MS
The short and initial interaction between the brain endothelium and
the leukocyte is mediated by selectins and their carbohydrate ligands or
by α4-integrins [58,99,100,103]. Although P-selectin is preferentially
expressed in meningeal and choroidal vessels under normal condi-
tions [40,57,59] and it is upregulated in the whole CNS vasculature upon
neuroinﬂammation, its role in supporting leukocyte extravasation
remains controversial as recent studies have shown that despite the
blockade or absence of P-selectin, mice developed clinical EAE
indistinguishable from controls [58,100]. In contrast, E-selectin expres-
sion is only observed in meningeal vessels, but not in parenchymal
vessels under inﬂammatory conditions [72]. In EAE it has been
demonstrated that E-selectin-deﬁcient animals displayed no differences
in symptomatology when compared to their WT counterparts [53].
Studies in humans correlate with themouse ﬁndings as immunostaining
analyseshave shownexpressionof E- andP-selectin inmeningeal vessels
of normal individuals and suggest that immunosurveillance is mediated
by thesemolecules [103]. InMS, E-selectin is upregulated inmicrovessels
isolated from MS autopsy material [202] and studies analyzing the
soluble forms of P- and E-selectin have demonstrated higher levels of
these molecules in the blood and CSF of MS patients, although a clear
association between the levels found and the type of MS still remain
controversial [51,54,128,129]. It has been also shown that CD8+ but not
CD4+ T cells from MS patients show increased rolling on endothelium
expressing P-selectin in vitro and that antibodies directed against
P-selectin glycoprotein ligand-1 (PSGL-1) block the recruitment of
CD8+ T cells throughmurine brain vessels [23]. On the other hand, early
immune cell inﬁltration in EAE mostly occurs through pial vessels and
most of the CD4+T cells involved in this process also expressα4β1 [179].
Itwas then shown thatα4-integrins actively participate in the rolling and
tethering of immune cells bymediating the initial capture and G-protein
dependent arrest of encephalitogenic T cell blasts crossing the white
matter microvasculature [193] as well as endogenous leukocytes and
encephalitogenic T cells in all the CNS vasculature [99,100,153]. The EAE
data correlate with MS, as analyses of human brain sections have shown
expression of α4β1 integrin in T cells located in perivascular cuffs and
brain parenchyma, while ECs expressed its receptor, vascular cell
adhesion molecule 1 (VCAM-1) [37,52,198]. These observations are
supported by experiments showing that human CD4+ T cells preferen-
tially roll using α4 integrins, whereas CD8+ T cells do it through the P-
selectin–PSGL1 interaction [23]. Thus, leukocyte tethering and rolling in
meningeal microvessels appears to be E- and P-selectin dependant and
their expression can be upregulated during neuroinﬂammatory condi-
tions like MS and EAE. On the other hand, while ECs of parenchymal
vessels express E- and P-selectin only under neuroinﬂammatory
conditions, neutralization of selectins has no effect in the development
of EAE. Conversely, blockade of α4-integrins inhibit immune cell rolling
in white matter microvessels, reducing the clinical severity of EAE and
MS. Overall, the crucial role played by α4-integrins in the binding of
inﬂammatory leukocytes to the CNS vasculature has resulted in the
generation of therapies currently used in the treatment of MS and in the
proof of concept that migration-targeting therapies are effective in
controlling lesion formation in EAE and human MS.
12. Leukocytes arrest and binding are mediated by integrin
activation and CAMs
CNS-ECs actively participate in neuroinﬂammatory reactions and can
directly inﬂuence immune cell migration by regulating the expression ofcell adhesion molecules (CAMs), cytokines and the secretion and
presentation of chemokines [39,121]. Chemokines are small heparin-
binding proteins involved in various stages of leukocyte transendothelial
migration into different organs, including the brain [163]. They are
particularly recognized for their role in activating leukocyte tethering and
rolling on endothelial surfaces. In this regard, chemokines immobilized
on endothelial surfaces interact with their receptor located on immune
cells; this G-protein receptor activation triggers Gαi-dependent intra-
cellular signaling [153,193]. The activation of this signaling pathway
stimulates conformational changes in the integrinsexpressedby immune
cells that result in a transition from a low to high afﬁnity/avidity state
facilitating the arrest of leukocytes to the endothelium [43,176]. The
redundancy of these molecular activation signals of integrin avidity is
apparent as more than 10 different chemokines are known to affect the
integrin dependant arrest of various immune cells [42,160].
The enhanced binding properties of integrins and the upregulation of
their counterparts in the endothelium under inﬂammatory conditions
provide the ideal environment to increase the local transmigration of
immune cells across BBB-ECs. While unactivated (resting) human and
mouse BBB-ECs express low levels of the CAMs, inﬂammatory conditions
(IFN-γ/TNF-α) dramatically upregulate the expression of intercellular
adhesion molecule 1 (ICAM-1) (Fig. 2A), VCAM-1 (Fig. 2C) and the
recently described [41], activated leukocyte cell adhesion molecule
(ALCAM) (Fig. 3A) [76,156,209,210]. Such phenotype is associated with
changes in the anatomical components of the BBB as the expression and
morphology of TJ proteins and cytoskeletal components are disturbed
(Fig. 3A). Likewise, the binding and migration of leukocytes increases
through this inﬂamed endothelium [3,41,75,210]. Regarding in situ
expression, ICAM-1 expression in ECs and its counter-ligand lymphocyte
function-associate molecule 1 (LFA-1) in leukocytes were ﬁrst described
within MS lesions 20 years ago [181]. Likewise, ICAM-1 is known to be
upregulated in CNS-ECs during EAE relapses. During subsequent
remission ICAM-1 expression was however downregulated; each
subsequent relapse was then characterized by corresponding upregula-
tion [36]. Highnumbers of perivascular inﬁltrating cells positive for LFA-1
[126] andα4β1-integrin, the ligands for ICAM-1 andVCAM-1, but not for
L-selectinorα4β7-integrinhavebeenalsodetected inMS lesions [57,61].
Our own analysis ofMS tissues conﬁrms previous ﬁndings and correlates
with in vitro data, as ICAM-1 and VCAM-1 are upregulated in blood
vessels of MS lesions displaying both low and high levels of immune cell
inﬁltration (Fig. 2B andD)when comparedwith counterparts in NAWM.
Interestingly, upregulation of ALCAM in BBB-ECs was found to be
localized at the areas of contact with immune cells and coincided with
abnormal expression of TJ proteins (Fig. 3B), suggesting that ALCAM-
mediated leukocyte migration was associated with a breach in the BBB.
Moreover, in pre-active lesions where blood vessels display small
perivascular inﬁltrates, leukocytes are mostly enclosed between the
vessel and the parenchymal BM (Fig. 2B andD upper panels), whereas in
active lesions fragments of ECM components can be detected in the
periphery of the vessel, indicating extensive vascular reorganization
(Fig. 2B and D lower panels).
13. Additional CAMs involve in leukocyte migration to the CNS
While leukocyte migration across CNS endothelium has long been
thought to depend on prototypic BBB-associated endothelial CAMs (such
as ICAM-1, VCAM and PECAM-1), recent studies have identiﬁed
additional CAMs that regulate leukocyte transmigration across ECs
during neuroinﬂammation. JAM-A has been implicated in the transmi-
gration of different leukocyte subsets. The role of JAM-A depends on the
model studied and is highly dependent on the nature of the neuroin-
ﬂammatory stimulus [142]. CD44 is thehyaluronic receptor expressedon
leukocytes and ECs and antibodies directed against this molecule limit
migration of T cells to the CNS in EAE [29]. In MS CD44 expression is
upregulated on T cells during relapses [182]. CD47 is an adhesion
receptor expressed in brain ECs. Upon interaction with its ligands, the
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ulates the migration of macrophages, dendritic cells and T cells into the
inﬂamed CNS [44,188]. In addition, CD47 also inhibits phagocytosis and
cytokine production inAPCs [48]. Due to these inhibitory functions, CD47
has been considered as a “don't eat me signal” [145,214] that is
downregulated in active MS lesions [105] and contrast with its role
promoting leukocyte inﬁltration and neuroinﬂammation.
Molecules with adhesive and enzymatic functions such as CD73 and
vascular adhesion protein-1 (VAP1) are also involved in leukocyte
migration [133]. CD73 is an ectoenzyme that metabolizes adenosine
monophosphate (AMP) precursor into adenosine, a molecule known to
be anti-inﬂammatory and neuroprotective. IFN-β treatment in MS
patients upregulates CD73 expression in CNS-ECs [139] and thisFig. 3. ALCAM expression is upregulated in ECs under neuroinﬂammatory conditions. The exp
(B). ALCAM is depicted in green, the TJ protein ZO1 in red, actin (stained with phalloidin) i
expression on the surface of BBB-ECs untreated (mock) or inﬂamed for 16 h with TNF-α an
altered in inﬂamed BBB-ECs (right panels). (B) ALCAM is upregulated in ECs of vessels asso
(asterisk), containing leukocytes (white dots) surrounded of ALCAM+ endothelial memb
associated with disrupted architecture and partial loss of intercellular junctions (arrows).correlated with reduce transmigration of CD4 T cells, rendering CD73
expression protective in MS [139]. Studies in EAE correlate with the
ﬁndingsmade in human, but surprisingly, CD73 inmurineCNS ismainly
expressed in choroid vessels and not in their parenchymal counterparts
[133]. Another polyfunctional adhesion molecule is VAP1, a semicarba-
zide-sensitive amine oxidase ﬁrst detected in adhesion assays to inhibit
lymphocyte binding to high endothelial venules [168]. Upon inﬂam-
matory conditions VAP-1 is rapidly translocated to the luminal surface
of ECs [93], where it functions as an adhesion molecule and also
contribute to leukocyte-EC interaction by inducing expression of
adhesion molecules (P- and E-selectin and ICAM-1) and chemokines
(CXCL8) [94,95,110]. Finally, VAP-1 relevance to neuroinﬂammation
was recently demonstrated as (i) inhibitors of its enzymatic activityression of ALCAM is shown in cultures of human primary BBB-ECs (A) and in aMS lesion
n light blue (in A) and the nuclei in blue (in B). Scale bars indicate 10 μm. (A) ALCAM
d IFN-γ. The pattern expression of the TJ protein ZO1 and the cytoskeleton (F-actin) is
ciated with MS lesions. High power views of the inset in the upper panel show a vessel
ranes and extravasating cells (arrowheads). Areas of immune cell extravasation are
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been detected in serum of patients with active MS [6].
14. Chemokine production by BBB-ECs
Even though BBB-ECs are able to express MHC class II and B7 co-
stimulation molecules under inﬂammatory conditions they are consid-
ered to be poor or non-professional antigen presenting cells [157],
unless this antigen presentation is supported by the presence of IL-2 or
by fully competent APCs. Nevertheless, BBB-ECs and astrocytes of the
NVU are potent producers of cytokines and chemokines. Inﬂammatory
cytokines (IL-1, TNF-alpha, IFN-gamma, IL-17, Il-22) produce by CNS
resident cells or by migrating leukocytes are known to induce cytokine
and chemokine secretion by CNS-ECs. In the context of CNS inﬂamma-
tion, BBB-ECs produce and secrete pro-inﬂammatory cytokines and
chemokines and have the capacity to immobilize chemokines on the
luminal vascular surface [38,97,98]. BBB-ECs produce the cytokines IL-6,
IL1α/β, GM-CSF and the chemokines MCP-1/CCL2, MIP-1α/CCL3, CCL5/
RANTES, CXCL8/IL-8, CXCL10/IP-10 in response to inﬂammatory
challenge [38,42,90,98,123]. Chemokines and cytokines are locally
secreted and responsible for the recruitment and activation of immune
cell. This is the basis for the inﬂammatory cascade that leads to the focal
inﬂammation of BBB-ECs and the recruitment of bystander immune
cells. The inﬁltrated bystander cells secrete additional cytokines and
chemokines that may further enhance CNS inﬂammation or promote a
gradual resolution of the inﬂammation. Although immune cell
inﬁltration plays an essential role in MS lesion development, there are
experimental evidences that suggest that BBB dysfunctions precede cell
inﬁltration and that BBB activation actively participate in the initiation
of lesion formation.
15. Leukocyte migration through the BCB in neuroinﬂammation
Aside from the morphological changes previously described in the
CP during neuroinﬂammation, the low number of immune cells
detected in this structure have made difﬁcult to determine the role
playedby the BCB in EAE andMS. In this regard, leukocyte entry through
the CP ﬁrst requires binding and migration through the fenestrated
endothelium. P-selectin has been the only adhesionmolecule described
in choroidal vessels under normal conditions and it appears to play role
in facilitating migration of CD4 T cells [103]. The CAMs, ICAM-1 and
VCAM-1 have not been detected in this endothelium under normal
conditions [61,103,189], while in MS, but not in EAE, VCAM-1 seems to
play a role in leukocyte transmigration as upregulated expression was
detected in the choroidal endothelium ofMS patients [199]. Once in the
choroidal stroma, leukocytes migrate to the abluminal side of the
choroid cells where a basal lamina presents as a barrier for the
inﬁltrating cells. To date the mechanisms to cross this extracellular
matrix have not been elucidated, but it can be speculated that immune
cells used MMPs and other ECM degrading enzymes to transverse the
basal lamina. It remains equally undetermined how leukocytes
transmigrate from the abluminal side to the ventricle. In this sense,
two possible mechanisms could be taking place, migration in between
choroidal cells and affecting the junctional complex or transcellularly
through the choroidal epithelium. Early studies in EAE have shown that
theCAMs, ICAM-1 andVCAM-1 areupregulated in the choroid epithelial
cells, but the expression is mostly limited to the apical side of the cells
[62], suggesting that these CAMs may promote immune cell binding in
the apical side of the choroid cells. Recent ﬁndings in MS contradict the
EAE data as VCAM-1 was only upregulated in the choroidal endothe-
lium, but not in the choroidal cells. VCAM-1may be an important player
in promoting leukocyte entry into the ventricular system as therapy
with natalizumab considerably reduces the number of lymphocytes in
the CSF [67]. Although other routes of immune cell migration into the
CNS, such as the leptomeninges, the ependyma and the circumven-
tricular organs cannot be discounted [8,103,173]. Thus, the role playedbyCAMs in themigrationof leukocytes through theBCB requires further
investigation and better correlation between MS and its murine model.
The expression of non-classical adhesion molecules has been also
studied in the CP. CD73 is a cell surface enzyme that catalyzes the
breakdown of AMP to adenosine. CD73 expression is not detected on
brain ECs of EAEmice, but high expression is found in the CP epithelium
where it seems to regulate lymphocyte immunosurveillance between
the blood and the CSF [133].
In addition to CAMs, the chemokine systemalso plays a fundamental
role in leukocyte migration through the BCB. Recently, evidence for a
chemokine receptor 6-CCL20-driven inﬂux of pathogenic Th17 lym-
phocytes in EAE has been reported [164]. These important ﬁndings
suggest that BCB might be a place of migration in EAE, in addition to
BBB-related events involved in lesion formation. Conﬁrmation of this
novel mechanism for immune cell recruitment to the CNS in additional
models of EAE and in human MS is however both awaited and needed.
16. Current and future BBB-related treatments
Current treatments of neuroinﬂammatorydiseases aimat dampening
the inﬂammatory cascade in the CNS and BBB-ECs are primary targets to
limit the inﬁltration of CNS-speciﬁc leukocytes and to limit local
inﬂammatory reactions. Most of the current therapies for MS have a
rather broad mechanism of action and are anti-inﬂammatory, immuno-
suppressive or immunomodulating agents. Of interest to us is the
integrin blocking antibody natalizumab. Natalizumab is a humanized
monoclonal antibody against the leukocyte VLA-4 (VCAM-1 ligand).
Treatmentwith this antibody (natalizumab)blocks theVLA-4dependent
migration of immune cell across the BBB-ECs and reduces the amount of
lesions detected by MRI, but because of adverse secondary effects this
drug isnowhighly controlled. This antibody is averypotent agent to limit
leukocyte transmigration and indicate that endothelial CAM association
with leukocyte integrins is a valid and effective method to limit
neuroinﬂammatory reactions [58,161,190]. Despite the efﬁcacy of
Natalizumab to control signs and symptoms of MS, its use is
unfortunately limited by the appearance of clinically important viral
CNS infection, such as progressive multifocal leukoencephalopathy
(PML). Emergence of PML in Natalizumab-treated MS patients is
associated with a relative but persistent cellular immunosupression of
the CNS compartment, related to VLA-4 neutralization.
However, based on the idea that immune cell exclusion from
tissues should preclude inﬂammation, tissue entry of leukocytes is a
particularly interesting target to modulate CNS-speciﬁc immune
reactions, especially if more speciﬁc adhesion molecules can be
identiﬁed on subsets of immune cells. Important research efforts are
underway to identify novel adhesion molecules of the BBB and their
counter-ligand on leukocytes using large scale, high-throughput
methods (genomics and proteomics). Identiﬁcation of adhesion
molecules that would control the transmigration of selected leukocyte
subsets would certainly be beneﬁcial in organ-targeted inﬂammatory
diseases and would probably demonstrate better long-term safety
proﬁles, especially as regards the control of CNS inﬂammation and the
progression of solid and metastatic tumors.
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